Benign Prostatic Hyperplasia Treatment Market
Benign Prostatic Hyperplasia Treatment Market By Treatment (Drug Classes (Alpha Blockers, 5-Alpha-reductase Inhibitors (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitors), Minimally-invasive Surgeries), By Laser Therapy, By End user & By Region - Global Market Insights 2022 to 2032
Analysis of Benign Prostatic Hyperplasia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
FREE CustomizationBenign Prostatic Hyperplasia Treatment Market Outlook (2022 to 2032)
The global benign prostatic hyperplasia (BPH) treatment market size was valued at US$ 27.7 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5% from 2022 to 2032.
The global benign prostatic hyperplasia (BPH) treatment market is estimated to be worth US$ 47.17 Billion by the end of 2032.
In 2021, the global benign prostatic hyperplasia treatment market revenue accounted for 24% of the global cancer treatment market. The growing preference for minimally invasive surgeries is expected to drive demand for BPH surgical treatment procedures in the coming decades.
| Report Attributes | Details |
|---|---|
| Anticipated Base Year Value (2021) | US$ 27.7 Billion |
| Expected Market Value (2022) | US$ 29 Billion |
| Projected Forecast Value (2032) | US$ 47.24 Billion |
| Global Growth Rate (2022 to 2032) | 5% CAGR |
| Expected Market Share of the U.S. Market (2032) | 4.9% |
| Anticipated Market CAGR of Europe (2022 to 2032) | 4.6% |
| Major Benign Prostatic Hyperplasia Treatment Service Providers | Abbott Laboratories; Allergan Plc.; Astellas Pharma Inc.; Asahi Kasei Corporation; Boehringer Ingelheim GmbH; GlaxoSmithKline Plc.; Pfizer Inc.; Boston Scientific Corporation; Teleflex Incorporated; Endo International Plc.; Urologix LLC; LISA Laser; Olympus Corporation; Teva Pharmaceutical Industries Ltd.; Merck & Co. Inc. |
Revenue Analysis of Benign Prostatic Hyperplasia Treatment from 2017 to 2021 Vs Market Projections for 2022 to 2032
The rising prevalence of benign prostatic hyperplasia (BPH) is a major factor driving the consumption of BPH treatment drugs and devices, and this trend has been accelerating in recent years. From 2017 to 2021, the global BPH prostate treatment market grew at a CAGR of 3.8%.
Some of the important factors that influence BPH treatment market growth include increased focus on healthcare, an aging population, deteriorating lifestyle, poor eating habits, hereditary inheritance of the illness, increased research and innovation, and greater availability of therapeutic approaches.
Over the projected timeframe, these factors are anticipated to favor demand for BPH homeopathy remedies, BPH relief medicine, and benign prostatic hyperplasia natural remedies.
Which are Some Prominent Drivers of the Benign Prostatic Hyperplasia Treatment Market?
The rising prevalence of benign prostatic hyperplasia is driving the market growth
BPH is a nonmalignant expansion of prostate tissue that is a prevalent trigger of lower urinary tract symptoms in men. BPH is regarded as a normal part of male aging and is hormonally reliant on the production of testosterone and dihydrotestosterone (DHT).
By the age of 60, approximately half of men have histopathologic BPH, and 90% have it by the age of 85. BPH symptoms are estimated to affect approximately 30 million men worldwide and 14 million men in the United States. (Image courtesy of WebMD LLC.)
As BPH is a representative illness that appears in men during the aging process, the increasing aging population, particularly the geriatric male segment, can be regarded as a significant driver of BPH incidence.
For instance, China is assumed to have the world's largest geriatric population; the population aged 65 and up is anticipated to account for 26.8% of the overall population by 2050, up from 10.1% in 2015. (Source: US Census Bureau). The WHO predicts that by 2050, China will have 100 million individuals aged 80 and up.
Will patent expirations have a long-term impact on the benign prostatic hyperplasia treatment market's sales revenue?
Loss of Patent Exclusivity Making Generic Drugs Profitable
Patent expirations have long influenced the revenues of the benign prostatic hyperplasia treatment market. According to the research, crucial BPH treatment drugs such as Avodart, Cialis, Jalyn, and Rapaflo will lose their patents in 2024. The absence of branded drugs creates lucrative opportunities for regional and local participants to increase investments in generic drugs and biosimilar items.
The low-cost impact of generic medicines restricts the market opportunities for branded drugs, which causes concern for leading players who invest heavily in R&D. Although generic drug sales aid in the expansion of the BPH treatment market, their revenue input is significantly lower when compared to branded drugs.
What are the Challenges Faced by the Benign Prostatic Hyperplasia Treatment Market?
The detrimental effects of BPH medications will constrain market growth
While both drugs and surgery can diagnose BPH, both have severe side effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes are frequently used to treat BPH.
Drowsiness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all common complications of alpha-blockers. Dizziness and orthostatic hypotension are particularly concerning in the elderly because they can result in serious morbidities like falls and subsequent injuries.
Comparative View of Benign Prostatic Hyperplasia Treatment Markets
Benign Prostatic Hyperplasia Treatment Market :
| Attributes | Benign Prostatic Hyperplasia Treatment Market |
|---|---|
| CAGR (2022 to 2032) | 5% |
| Market Value (2032) | US$ 47.17 Billion |
| Growth Factor | The rising prevalence of benign prostatic hyperplasia (BPH) is a major factor driving the consumption of BPH treatment drugs and devices, and this trend has been accelerating in recent years. |
| Opportunity | Enhancing emphasis on healthcare and soaring relevant research in this country are predicted to be significant trends in the treatment industry through 2032. |
Benign Positional Vertigo Treatment Market :
| Attributes | Benign Positional Vertigo Treatment Market |
|---|---|
| CAGR (2022 to 2032) | 4.4% |
| Market Value (2032) | USD 1,800 Million |
| Growth Factor | The rising number of cases of benign positional vertigo is spurring the benign positional vertigo treatment market forward. The benign positional vertigo treatment market is growing due to the short turnaround time and lower cost of the procedure compared to traditional methods. |
| Opportunity | The expanding number of patients seeking benign positional vertigo treatment, as well as its growing demand, presents a lucrative potential growth for market participants. |
Which Regional Market is the Most Profitable for Benign Prostatic Hyperplasia Treatment Manufacturers?
Growing technological innovations are supplementing the development efforts of Japanese manufacturers such as Olympus Corporation, Astellas Pharma, Inc., and Asahi Kasei Corporation. The benign prostatic hyperplasia treatment market in Asia Pacific is broadening at a rapid pace, with a CAGR of 7.3% anticipated during the forecast timeframe, owing to rising demand from medical tourism and severe R&D efforts to ensure long-term supply.
North America held the largest portion of the global benign prostatic hyperplasia therapeutics market share in 2021 and is predicted to continue to dominate throughout the projected timeframe. This is due to a rise in the incidence of BPH, an unpleasant lifestyle that leads to obesity, the existence of prominent stakeholders, and an increase in healthcare expenses in the region.
The growing incidence of benign prostatic hyperplasia in men, combined with rising risk factors, will dampen the demand for sophisticated medical devices and respond as key causes driving the expansion of the benign prostatic hyperplasia treatment market. Moreover, an increase in the requirement for minimally invasive treatment, an increment in the aging populations, and advancements associated with novel and advanced BPH treatment technologies will all contribute to the growth of the benign prostatic hyperplasia treatment market in Europe.
Country-wise Analysis
Why India is anticipated to witness huge market growth?
The financial privileges of TURP surgery in India to drive market growth
According to the Fact.MR study, the typical expense of transurethral resection of the prostate (TURP) in the United States ranges from US$ 8,000 to US$ 12,000, whereas the same surgery in India costs markedly less (between US$ 1,500 and US$ 6,000). Amidst the use of cutting-edge technology and diagnostic devices by surgeons to provide optimal clinical outcomes, the financial benefits of TURP surgery in India are substantial.
This is generating a new source of revenue for the benign prostatic hyperplasia treatment market through medical tourism, which is driven primarily by patients from Western nations such as the United States and the United Kingdom. In addition, hospitals, both private and public, do not have long waitlists, and India has relaxed visa policies, making the country more appealing for medical tourism. Thus, the market for benign prostatic hyperplasia treatment in India is anticipated to grow quickly.
Why United States will emerge as a Key Market Player?
Because of its aging population, the United States is experiencing rapid expansion
Because of the rising prevalence of benign prostatic hyperplasia, there is projected to be a high demand for BPH treatment in the United States. The country is witnessing an increment in its older population, which is more vulnerable to this circumstance and thus a highly lucrative market for BPH treatment providers.
Rising R&D activities and the accessibility of BHT surgical intervention are also expected to have an impact on market potential in the United States. Moreover, enhancing emphasis on healthcare and soaring relevant research in this country are predicted to be significant trends in the treatment industry through 2032.
Country-wise Forecast CAGRs for the Benign Prostatic Hyperplasia Treatment Industry
| Country | CAGR |
|---|---|
| China | 5% |
| U.S. | 4.9% |
| Australia | 4.4% |
| France | 4.7% |
Category-wise Insights
Which end-user segment will generate high revenue?
Hospitals will strive to be General Recognized Centers of Care
The market has been classified by end user into hospitals, ambulatory surgical centers, specialty clinics, and others, with hospitals accounting for the lion's share. The growth of the benign prostatic hyperplasia treatment market will be attributed to the high accumulation of hospitals, which were early adopters of advanced technological therapeutic approaches and were primarily preferred care facilities.
However, patients' lack of willingness to stay in hospitals for lengthy periods benefits specialized clinics. During the forecast period, specialty clinics are expected to grow at a higher CAGR of more than 6.9%.
Will the Transurethral Resection of the Prostate (TURP) segment witness high demand over the forecast period?
Soaring healthcare expenses to drive TURP segment's demand
Another economic expansion factor is the advancement of transurethral resection of the prostate (TURP) as an efficient therapeutic methodology. Other variables, such as rising healthcare expense capacities for individuals, as well as major progress in healthcare infrastructure, notably in developing countries, are predicted to accelerate this segment's growth even further.
Market Competition
Key players in the Benign Prostatic Hyperplasia Treatment market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Manufacturers of BPH treatment devices and drugs are investing in research and development to develop innovative treatments that will provide optimal therapeutic options for people suffering from the disease. Some of the novel developments by key manufacturers are
- In January 2021, PHAREX Health Corporation introduced Pharex Tamsulosin for BPH treatment in collaboration with the Philippine Urological Association (PUA).
- UroLift launched the Advanced Tissue Control (ATC) System in 2020.
- Asahi Kasei Pharma received Chinese approval for Flivas in 2020.
- Alembic was granted FDA approval for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg in 2019.
Key Segments Profiled in the Benign Prostatic Hyperplasia Treatment Industry Survey
-
By Treatment :
- Drug Class
- Alpha Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally-invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Robotic Surgeries
- Transurethral Microwave Thermotherapy (TUMT)
- Prostatic Urethral Lift
- Others
- Laser Therapy
- Others
- Drug Class
-
By End User :
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Others
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Key Insights
- 6. Global Market Analysis, by Treatment
- 6.1. Drug Class
- 6.1.1. Alpha-Blockers
- 6.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 6.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 6.1.4. Others
- 6.2. Minimally Invasive Surgeries
- 6.2.1. Transurethral resection of the prostate (TURP)
- 6.2.2. Transurethral incision of the prostate (TUIP)
- 6.2.3. Robotic Surgeries
- 6.2.4. Transurethral microwave thermotherapy (TUMT)
- 6.2.5. Prostatic Urethral lift
- 6.2.6. Others
- 6.3. Laser Therapy
- 6.4. Others
- 6.1. Drug Class
- 7. Global Market Analysis, by End-user
- 7.1. Hospitals
- 7.2. Ambulatory Surgical Centers
- 7.3. Specialty Clinics
- 7.4. Others
- 8. Global Market Analysis, by Region
- 8.1. North America
- 8.2. Europe
- 8.3. Asia Pacific
- 8.4. Latin America
- 8.5. Middle East & Africa
- 9. North America Market Analysis
- 10. Europe Market Analysis
- 11. Asia Pacific Market Analysis
- 12. Latin America Market Analysis
- 13. Middle East & Africa Market Analysis
- 14. Competition Landscape (Pharmaceutical Companies)
- 14.1. Abbott
- 14.2. Allergan Plc
- 14.3. Astellas Pharma, Inc.
- 14.4. Asahi Kasei Corporation
- 14.5. Boehringer Ingelheim GmbH
- 14.6. GlaxoSmithKline Plc.
- 14.7. Pfizer, Inc.
- 14.8. Sanofi SA
- 14.9. Teva Pharmaceutical Industries Ltd.
- 14.10. Merck & Co., Inc.
- 15. Competition Landscape (Medical Devices/Service Provider Organizations)
- 15.1. Boston Scientific Corporation
- 15.2. Teleflex Incorporated
- 15.3. Endo International Plc.
- 15.4. Urologix, LLC
- 15.5. LISA Laser
- 15.6. Olympus
List Of Table
TABLE 01: Prostate Cancer Therapeutics: Pipeline Analysis - Phase III (1/2)
TABLE 02: Prostate Cancer Therapeutics: Pipeline Analysis - Phase III (2/2)
TABLE 03: Prostate Cancer Therapeutics: Pipeline Analysis - Phase II (1/2)
TABLE 04: Prostate Cancer Therapeutics: Pipeline Analysis - Phase II (2/2)
TABLE 05: Prostate Cancer Therapeutics: Pipeline Analysis - Phase I
TABLE 06: 2015 Patient Population Break Down
TABLE 07: Number of Surgeries (Unit Procedures) Performed in United States (2022)
TABLE 08: Summary of Current BPH Treatments in U.S.
TABLE 09: Global Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 10: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 11: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 12: Global Market Size (US$ Mn) Forecast, by End-user, 2022 to 2032
TABLE 13: Global Market Value (US$ Mn) Forecast, by Region, 2022 to 2032
TABLE 14: North America Market Value (US$ Mn) Forecast, by Country, 2022 to 2032
TABLE 15: Global Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 16: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 17: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 18: North America Market Value (US$ Mn) Forecast, by End-user, 2022 to 2032
TABLE 19: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 to 2032
TABLE 20: Europe Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 21: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 22: Europe Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 23: Europe Market Value (US$ Mn) Forecast, by End-user, 2022 to 2032
TABLE 24: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 to 2032
TABLE 25: Asia Pacific Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 26: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 27: Asia Pacific Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 28: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2022 to 2032
TABLE 29: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 to 2032
TABLE 30: Latin America Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 31: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 32: Latin America Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 33: Latin America Market Value (US$ Mn) Forecast, by End-user, 2022 to 2032
TABLE 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 to 2032
TABLE 35: Middle East & Africa Market Size (US$ Mn) Forecast, by Treatment, 2022 to 2032
TABLE 36: Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Class, 2022 to 2032
TABLE 37: Middle East & Africa Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022 to 2032
TABLE 38: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2022 to 2032
List Of Figures
FIG. 01: Global Market Size (US$ Mn) Forecast, 2022 to 2032
FIG. 02: Global Market Value Share, by Treatment, 2021
FIG. 03: Global Market Value Share, by Drug Class, 2021
FIG. 04: Global Market Value Share, by End-user, 2021
FIG. 05: Global Market Value Share, by Minimally Invasive Surgery, 2021
FIG. 06: Global Market Value Share Analysis, by Treatment, 2022 & 2032
FIG. 07: Global Market Revenue, by Drug Class, 2022 to 2032
FIG. 08: Global Market Revenue, by Minimally Invasive Surgeries, 2022 to 2032
FIG. 09: Global Market Revenue, by Laser Therapy, 2022 to 2032
FIG. 10: Global Market Revenue, by Others, 2022 to 2032
FIG. 11: Global Market Attractiveness Analysis, by Treatment, 2022 to 2032
FIG. 12: Global Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 13: Global Market Revenue, by Hospitals, 2022 to 2032
FIG. 14: Global Market Revenue, by Ambulatory Surgical Centers, 2022 to 2032
FIG. 15: Global Market Revenue, by Specialty Clinics, 2022 to 2032
FIG. 16: Global Market Revenue, by Others, 2022 to 2032
FIG. 17: Global Market Attractiveness Analysis, by End-user, 2022 to 2032
FIG. 18: Global Market Value Share (%), by Region, 2018 and 2026
FIG. 19: Global Market Attractiveness, by Region, 2022 to 2032
FIG. 20: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022 to 2032
FIG. 21: North America Market Value Share, by Country, 2022 & 2032
FIG. 22: North America Market Attractiveness, by Country, 2022 to 2032
FIG. 23: North America Market Value Share Analysis, by Product, 2022 & 2032
FIG. 24: North America Market Attractiveness, by Product, 2022 to 2032
FIG. 25: North America Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 26: North America Market Attractiveness, by End-user, 2022 to 2032
FIG. 27: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022 to 2032
FIG. 28: Europe Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 29: Europe Market Attractiveness, by Country/Sub-region, 2022 to 2032
FIG. 30: Europe Market Value Share Analysis, by Product, 2022 & 2032
FIG. 31: Europe Market Attractiveness, by Product, 2022 to 2032
FIG. 32: Europe Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 33: Europe Market Attractiveness, by End-user, 2022 to 2032
FIG. 34: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022 to 2032
FIG. 35: Asia Pacific Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 36: Asia Pacific Market Attractiveness, by Country/Sub-region, 2022 to 2032
FIG. 37: Asia Pacific Market Value Share Analysis, by Product, 2022 & 2032
FIG. 38: Asia Pacific Market Attractiveness, by Product, 2022 to 2032
FIG. 39: Asia Pacific Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 40: Asia Pacific Market Attractiveness, by End-user, 2022 to 2032
FIG. 41: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022 to 2032
FIG. 42: Latin America Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 43: Latin America Market Attractiveness, by Country/Sub-region, 2022 to 2032
FIG. 44: Latin America Market Value Share Analysis, by Product, 2022 & 2032
FIG. 45: Latin America Market Attractiveness, by Product, 2022 to 2032
FIG. 46: Latin America Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 47: Latin America Market Attractiveness, by End-user, 2022 to 2032
FIG. 48: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022 to 2032
FIG. 49: Middle East & Africa Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 50: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2022 to 2032
FIG. 51: Middle East & Africa Market Value Share Analysis, by Product, 2022 & 2032
FIG. 52: Middle East & Africa Market Attractiveness, by Product, 2022 to 2032
FIG. 53: Middle East & Africa Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 54: Middle East & Africa Market Attractiveness, by End-user, 2022 to 2032
FIG. 55: Global Devices Market Share Analysis, by Company (2019)
FIG. 56: GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 57: GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2017 to 2021
FIG. 58: GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
FIG. 59: GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
FIG. 60: Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 61: Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
FIG. 62: Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 63: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 64: Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
FIG. 65: Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 66: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
FIG. 67: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 68: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
FIG. 70: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
FIG. 71: Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 72: Abbott Laboratories R&D Intensity and Sales & Marketing Intensity – Company Level, 2017 to 2021
FIG. 73: Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
FIG. 74: Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
FIG. 75: Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 76: Allergan plc Breakdown of Net Sales (%), by Geography, 2018
FIG. 77: Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2017 to 2021
FIG. 78: Allergana plc Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 79: Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 80: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
FIG. 81: Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2017 to 2021
FIG. 82: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
FIG. 83: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 84: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
FIG. 85: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
FIG. 86: Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2017 to 2021
FIG. 87: Merck & Co., Inc. Break-up of Net Sales, by Region, 2021
FIG. 88: Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 89: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2017 to 2021
FIG. 90: Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 91: Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 92: Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 93: Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 94: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2021
FIG. 95: Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2017 to 2021
FIG. 96: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2021
FIG. 97: Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 98: Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2021
FIG. 99: Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2021
FIG. 100: Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 101: Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2021
FIG. 102: Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
FIG. 103: Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 104: Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2021
FIG. 105: Olympus Corporation Breakdown of Net Sales (%), by Region, 2021
FIG. 106: Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2021
- FAQs -
What was the market worth for Benign Prostatic Hyperplasia Treatment in 2021?
As of 2021, the Benign Prostatic Hyperplasia Treatment market was worth US$ 27.7 Billion.
At what value is the Benign Prostatic Hyperplasia Treatment industry likely to close by 2022?
Fact.MR foresees Benign Prostatic Hyperplasia Treatment demand to reach US$ 29 Billion in 2022.
At what percentage will the market for Benign Prostatic Hyperplasia Treatment rise until 2032?
From 2022-2032, Fact.MR expects Benign Prostatic Hyperplasia Treatment revenue to flourish at a 5% CAGR.
What is the expected market value for Benign Prostatic Hyperplasia Treatment in 2032?
In 2032, Benign Prostatic Hyperplasia Treatment market worth is poised to reach US$ 47.17 Billion.
How do growth prospects for Benign Prostatic Hyperplasia Treatment appear in the North America?
North American regional market is expected to rise 1.4X by 2032.
How do growth prospects for Benign Prostatic Hyperplasia Treatment appear in the China?
China is expected to possess 20% market share for Benign Prostatic Hyperplasia Treatment in 2032.
Benign Prostatic Hyperplasia Treatment Market